16 registrations that name somatropin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 16 registrations
Status
Phase
55US sites across 23 states
1
2 to 4
5 to 19
20 or more
All 16 registrations
RecruitingNCT07221851
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Phase 3
Ascendis Pharma A/S
About 186 people
Started Dec 12, 2025
In plain words A Phase 3 study of somatropin in people 2 to 17, run by Ascendis Pharma A/S. It plans to enroll about 186 people at 51 sites, 23 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 2 to 17. Conditions: Turner Syndrome; Short Stature Homeobox Gene Mutation; Idiopathic Short Stature; Small for Gestational Age at Delivery.
Chronological age between ≥2 and <18 years, at start of screening.
Naïve to growth hormone and growth hormone promoting therapies.
Prepubertal.
Able to stand without assistance.
5 more inclusion criteria and the exclusion criteria are on the listing.
This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and \<18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be distributed equally (1:1), to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year. The full summary is on the listing.
Where, as registered
23 US sites in 16 states; also South Korea (7), France (5), Italy (5), Spain (5), Germany (4), Romania (2).
RecruitingNCT04867317
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
Phase 3
VA Office of Research and Development
About 172 people
Started Jan 13, 2025
In plain words A Phase 3 study of somatropin in people 21 to 55, run by VA Office of Research and Development. It plans to enroll about 172 people at 16 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 55. Conditions: Adult Growth Hormone Deficiency; Mild Traumatic Brain Injury.
OEF/OIF/OND Veteran
Score of 18 or more on Combat Experiences sub-scale of Deployment Risk and Resilience Inventory-2 (DRRI-2)
One or more mild traumatic brain injury (mTBI) sustained during military service at least 12 months prior to the screening date, as noted via the CRAFT survey.
Growth hormone (GH) deficiency diagnosed by: macimorelin stimulation test (cut point 5.1 micrograms per liter), or glucagon stimulation test (cut point: 3 micrograms per liter (mcg/L) for body mass index up to 25; cut point 1 micrograms…
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Somatropin; Placebo
Registered summary
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
Where, as registered
16 US sites in 14 states.
RecruitingNCT07226089
Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.
Phase 3
Rabin Medical Center
About 254 people
Started Feb 1, 2026
In plain words A Phase 3 study of somatropin in people 3 to 11, run by Rabin Medical Center. It plans to enroll about 254 people at 32 sites, 12 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 11. Conditions: ISS; SGA.
Diagnosis of SGA or ISS. SGA, defined as born with a birth weight and/or length <-2 SDS below the mean for gestational age. ISS, defined as height < -2 SDS for age and gender without evidence of GHD
Females aged ≥3 years and <9 years. Males aged ≥3 years and <11 years
Pre-pubertal- Tanner stage 1 for breasts and testes.
A bone age of not more than chronological age recorded in previous 8 weeks.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Somatrogon; Genotropin
Registered summary
This study is a randomized, open-label, active controlled, parallel group study comparing the efficacy and safety of once weekly Somatrogon to daily Growth Hormone (Genotropin) in pre-pubertal children with short stature either born Small for Gestational Age (SGA) or with Idiopathic Short Stature (ISS). The planned study duration is 12 months with a screening period of up to 30 days. The study will consist of two groups: 140 children with SGA who are naïve to GH treatment will be randomized 1:1 to receive either Somatrogon or Genotropin for 12 months. The full summary is on the listing.
Where, as registered
12 US sites in 8 states; also France (6), Israel (6), India (4), Japan (4).
RecruitingNCT05355272
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
Phase 2
Baylor College of Medicine
About 20 people
Started Mar 11, 2024
In plain words A Phase 2 study of somatropin in people 18 to 64, run by Baylor College of Medicine. It plans to enroll about 20 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 64. Conditions: Gulf War Syndrome; Adult Growth Hormone Deficiency.
veteran of the Gulf War conflict with a history of deployment to Operation Desert Storm or Desert Shield between 1990-91
age less than or equal to 64 years old
have a diagnosis of Gulf War Illness assessed by study investigators
have adult growth hormone deficiency diagnosed by glucagon stimulation test (cut point 3.0 mcg/L if BMI is less than or equal to 25 or 1.0 mcg/L if BMI is greater than 25)
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Recombinant human growth hormone
Registered summary
The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency? 2. The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
RecruitingNCT06103513
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
Phase 3
Northwell Health
About 50 people
Started Dec 10, 2023
In plain words A Phase 3 study of somatropin in people 5 to 15, run by Northwell Health. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 5 to 15; healthy volunteers accepted. Conditions: Growth Disorders; Growth Failure; Growth Hormone Treatment; Growth.
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 5-15 years
In good general health as evidenced by medical history or diagnosed with growth hormone deficiency
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Somatropin
Registered summary
A prospective, randomized, open-label single-blinded study of 50 subjects with growth hormone deficiency, ages 5 to 15 years in which 25 subjects will initiate rhGH therapy at 0.3mg/kg/week and the remaining 25 subjects will initiate their rhGH treatment at 0.2 mg/kg/week for the first 12 months of treatment. Safety parameters, height velocity, and adult height prediction by bone age determination will be assessed at 4-month intervals for 1 year following the initiation of rhGH therapy.
Where, as registered
1 US site in 1 state.
RecruitingNCT06110910
Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)
Observational
Xiaoping Luo
About 10,000 people
Started Mar 1, 2023
In plain words An observational study of somatropin in people 2 and older, run by Xiaoping Luo. It plans to enroll about 10,000 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 2 and older. Conditions: Childhood Short Stature.
Children aged 2 years and older with various causes of short stature.
Height below the 3rd percentile (-1.88 SD) compared to the height of normal, healthy children of the same age and gender.
Belonging to one of the following indications: GHD, ISS, SGA, TS, PWS, NS, SHOX gene deletion, or other causes of short stature.
The exclusion criteria are on the listing.
What it tests, as registered
Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
Registered summary
Short stature is a relatively common pediatric condition, referring to individuals whose height is more than 2 (-2 SD) standard deviations below the average height of a similar age, gender, and ethnicity population in similar living conditions, or those below the third percentile (-1.88 SD). This study is an open-label, multicenter, prospective and retrospective, observational, cohort study aimed at assessing the long-term safety and efficacy of PEG-rhGH or rhGH treatment for Chinese children with short stature. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06037473
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
Observational
Beijing Children's Hospital
About 2,600 people
Started Aug 1, 2023
In plain words An observational study of somatropin in people up to 18, run by Beijing Children's Hospital. It plans to enroll about 2,600 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people up to 18. Conditions: Growth Hormone Treatment; Growth Disorders.
What it tests, as registered
Polyethylene glycol recombinant human growth hormone injection
Registered summary
In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.
Where, as registered
No US site; China (1).
RecruitingNCT06927310
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
Phase 3
Xiamen Amoytop Biotech Co., Ltd.
About 300 people
Started Apr 28, 2025
In plain words A Phase 3 study of somatropin in people 3 to 11, run by Xiamen Amoytop Biotech Co., Ltd.. It plans to enroll about 300 people at 38 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 11. Conditions: Idiopathic Short Stature.
Prepubertal children: boys aged ≥3 years and <11 years at screening with testicular volume <4 mL; girls aged ≥3 years and <10 years at screening with breast development at Tanner Stage I, i.e., no palpable breast glandular tissue.
Compared to chronological age, bone age is advanced by no more than 1 year or delayed by no more than 2 years (i.e., -2 years ≤ bone age - chronological age ≤ 1 year).
Height at screening is below -2 standard deviations (SD) from the mean for age and sex, with height reference to Appendix 1.
Body mass index (BMI) is within the 5th to 95th percentile for age and sex of healthy children, with reference to Appendix 2.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Inpegsomatropin Injection; Recombinant Human Growth Hormone Injection
Registered summary
This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection，once a week，compared with recombinant human growth hormone (rhGH) in children with idiopathic short stature (ISS). It plans to enroll 300 children with ISS, who will be randomized , stratified by gender and age, and assigned to either the experimental group or the positive controlled group. Each participant will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). The full summary is on the listing.
Where, as registered
No US site; China (38).
RecruitingNCT07323329
Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
Phase 2 and 3
Beni-Suef University
About 165 people
Started Oct 10, 2025
In plain words A Phase 2 and 3 study of somatropin in female participants 18 to 35, run by Beni-Suef University. It plans to enroll about 165 people at 1 site, none in the US.
Advanced maternal age (>40 years) or any other risk factor for Poor Ovarian Response (POR).
≤3 oocytes with a conventional stimulation protocol).
An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].
The exclusion criteria are on the listing.
What it tests, as registered
Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.; DHEA plus folic acid 400mcg per day; control group
Registered summary
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07309562
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Phase 3
Xiamen Amoytop Biotech Co., Ltd.
About 141 people
Started Jan 20, 2026
In plain words A Phase 3 study of somatropin in people 2 to 11, run by Xiamen Amoytop Biotech Co., Ltd.. It plans to enroll about 141 people at 49 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 2 to 11. Conditions: Small for Gestational Age.
Prepubertal (Tanner stage I) children: boys aged ≥2 and <11 years, and girls aged ≥2 and <10 years at screening.
Bone age is not more than 1 year advanced or more than 2 years delayed compared to chronological age (i.e., -2 years ≤ bone age - chronological age ≤ 1 year).
Birth weight and/or length below the 10th percentile for gestational age and sex, according to the reference values in Appendix 1.
Gestational age at birth ≥28 weeks.
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Inpegsomatropin Injection; Inpegsomatropin Injection; Recombinant Human Growth Hormone Injection
Registered summary
This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection，once a week，compared with recombinant human growth hormone (rhGH) in children with short stature born small for gestational age (SGA).It plans to enroll 141 children with short stature born small for gestational age (SGA), who will be stratified by gender and age and randomized in a 1:1:1 ratio to either Experimental Group 1, Experimental Group 2, or the Active Control Group. The full summary is on the listing.
Where, as registered
No US site; China (49).
RecruitingNCT07016802
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
Phase 1
Changchun GeneScience Pharmaceutical Co., Ltd.
About 64 people
Started Jun 9, 2025
In plain words A Phase 1 study of somatropin in people 18 to 70, run by Changchun GeneScience Pharmaceutical Co., Ltd.. It plans to enroll about 64 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70; healthy volunteers accepted. Conditions: Safety; Tolerability; Adult Growth Hormone Deficiency.
Healthy adult male subjects（Phase Ia），or Healthy adult subjects（Phase Ib） aged 18-45 years (inclusive of boundary values);
Body Mass Index (BMI): 19.0-24.0 kg/m² (inclusive of boundary values);
Good health status;
Able to understand and willing to sign the Informed Consent Form (ICF), and comply with study requirements and restrictions.
14 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GenSci134; Placebo; Recombinant Human Growth Hormone Injection (Norditropin®)
Registered summary
To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers， a multiple-doses subcutaneous injection of GenSc134 is in healthy volunteers，a single subcutaneous injection of GenSc134 is in AGHD patients.
Where, as registered
No US site; China (1).
RecruitingNCT05746650
Improving Tissue Repair After Injury in the Muscle-tendon Interface Muscle Tissue Injury
No phase
Bispebjerg Hospital
About 40 people
Started Feb 24, 2023
In plain words A study of somatropin in people 18 to 35, run by Bispebjerg Hospital. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 35; healthy volunteers accepted. Conditions: Muscle Injury.
Healthy men and women scheduled to undergo reconstructive knee surgery
BMI 18-35
The exclusion criteria are on the listing.
What it tests, as registered
Electrical stimulation; Growth hormone (somatropin); Control (No electrical stimulation, nor growth hormone)
Registered summary
The study is a 2-week human study where 40 patients who are scheduled to undergo reconstructive knee surgery are randomized to administration of GH or placebo following or without neuromuscular electrical stimulation of hamstring muscles.The overall aim is to determine, the role of muscle connective tissue protein synthesis in muscle injury and repair.
Where, as registered
No US site; Denmark (1).
Not yet recruitingNCT06558422
Human Models of Selective Insulin Resistance: Pancreatic Clamp
Phase 1
Columbia University
About 36 people
Starts Jan 1, 2027 (estimated)
In plain words A Phase 1 study of somatropin in people 18 to 65, run by Columbia University. It plans to enroll about 36 people at 1 US site.
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with insulin resistance. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07481656
Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)
Phase 4
Anhui Provincial Hospital
About 160 people
Starts Apr 10, 2026 (estimated)
In plain words A Phase 4 study of somatropin in people 60 and older, run by Anhui Provincial Hospital. It plans to enroll about 160 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older. Conditions: Acute Brain Injuries; Moderate to Severe Traumatic Brain Injury.
Age ≥ 60 years, male or female.
Hospitalized patients with acute brain injury (including traumatic brain injury, ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage) who had a Glasgow Coma Scale (GCS) score ≤ 12 at any time during hospitalization.
Presence of hypoalbuminemia, defined as serum albumin < 35 g/L and/or prealbumin < 200 mg/L after admission.
Willing and able to provide informed consent (by patient or legal representative).
The exclusion criteria are on the listing.
What it tests, as registered
Recombinant Human Growth Hormone (rhGH) Injection; Standard Care (Treatment as Usual)
Registered summary
This study is a multicenter, randomized controlled trial aimed at evaluating the effectiveness and safety of recombinant human growth hormone (rhGH) in elderly patients who have suffered moderate to severe acute brain injuries complicated by hypoproteinemia. Eligible participants, aged 60 and older, with acute brain injuries and low serum albumin levels will be randomly assigned to either the growth hormone treatment group or the control group. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07450001
A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)
Phase 1 and 2
Changchun GeneScience Pharmaceutical Co., Ltd.
About 128 people
Starts Mar 6, 2026 (estimated)
In plain words A Phase 1 and 2 study of somatropin in people 3 to 12, run by Changchun GeneScience Pharmaceutical Co., Ltd.. It plans to enroll about 128 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 12. Conditions: Pediatric Growth Hormone Deficiency.
Informed consent of parent or legal representative of participant and child assent, as age appropriate must be obtained before any study-related activities.
At the time of signing the Informed consent form (ICF), the following conditions must be met:
BMI within the range of ±2 SD of the mean BMI for age and sex at screening
Height is at least 2 SD below the mean HT for age and sex (HT SDS ≤ -2.0) at screening according to the normal pediatric population standards
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GenSci134 Injection; Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)
Registered summary
This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD. Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with GHD. It will also evaluate PK/PD profile and immunogenicity to support dose selection for Phase III.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07450053
A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)
Phase 1 and 2
Changchun GeneScience Pharmaceutical Co., Ltd.
About 128 people
Starts Mar 6, 2026 (estimated)
In plain words A Phase 1 and 2 study of somatropin in people 3 to 12, run by Changchun GeneScience Pharmaceutical Co., Ltd.. It plans to enroll about 128 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 12. Conditions: Idiopathic Short Stature.
sInformed consent of parent or legal representative of participant and child assent, as age appropriate must be obtained before any study-related activities.
At the time of signing the Informed consent form (ICF), the following conditions must be met:
Phase Ib:
Diagnosis of ISS at the time of ICF signing .
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GenSci134 Injection; Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)
Registered summary
This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation study to evaluate the safety, tolerability, PK/PD profile, and immunogenicity of a single subcutaneous dose of GenSci134 in children with idiopathic short stature (ISS). Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with ISS. The full summary is on the listing.